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ABSTRACT
Nucleoside analogs (NAs) represent an important
category of prodrugs for the treatment of viral
infections and cancer, yet the biological potency of
many analogs is compromised by their inefficient
activation through cellular 2’-deoxyribonucleoside
kinases (dNKs). We herein report the directed evo-
lution and characterization of an orthogonal NA
kinase for 3’-deoxythymidine (ddT), using a new
FACS-based screening protocol in combination
with a fluorescent analog of ddT. Four rounds of
random mutagenesis and DNA shuffling of
Drosophila melanogaster 2’-deoxynucleoside
kinase, followed by FACS analysis, yielded an ortho-
gonal ddT kinase with a 6-fold higher activity for the
NA and a 20-fold kcat/KM preference for ddT over
thymidine, an overall 10000-fold change in substrate
specificity. The contributions of individual amino
acid substitutions in the ddT kinase were evaluated
by reverse engineering, enabling a detailed struc-
ture–function analysis to rationalize the observed
changes in performance. Based on our results,
kinase engineering with fluorescent NAs and FACS
should prove a highly versatile method for evolving
selective kinase:NA pairs and for studying funda-
mental aspects of the structure–function relation-
ship in dNKs.
INTRODUCTION
In battling existing and newly emerging viral infections
and cancer, nucleoside analogs (NAs) represent a promi-
nent and highly potent weapon. Administered as mem-
brane-penetrating nucleosidic prodrugs, the compounds
undergo intracellular activation by 20-deoxynucleoside
and 20-deoxynucleotide kinases into their bioactive tripho-
sphate anabolites. However, ineﬃcient phosphorylation of
NAs by endogenous 20-deoxynucleoside kinases (dNK)
limits the potency of existing prodrugs, results in the accu-
mulation of cytotoxic intermediates and is responsible for
the failure of a large percentage of new NAs in vivo (1–3).
Biochemical and pre-clinical trials have demonstrated
that co-administration of an exogenous, broad-speciﬁcity
dNK via gene therapy can enhance the eﬃciency of NA
prodrug activation (4–8). Nevertheless, even the most pro-
miscuous dNKs from viruses, bacteria and plants show
signiﬁcantly lower activity for NAs compared to their per-
formance with the natural substrates. In addition, the
broad substrate speciﬁcity of exogenous kinases can
create new problems as it interferes with the tightly regu-
lated 20-deoxynucleoside metabolism. As such, the identi-
ﬁcation of orthogonal NA kinases, enzymes with changed
rather than broader substrate speciﬁcity, represents a for-
midable challenge with great potential beneﬁts for present
and future therapeutics.
An alternative to searching for promising dNKs
in nature is the application of protein engineering and
directed evolution for generating novel enzymes with
NA speciﬁcity and eﬃciency. Laboratory evolution
experiments to redesign existing kinases have been
reported, using site-directed, saturation and random
mutagenesis, as well as homologous recombination and
chimeragenesis (9–14). However, these eﬀorts have been
hampered by the inability to directly screen or select
library members for NA phosphorylation. For two dec-
ades, researchers in the ﬁeld have relied on two techniques
for dNK library analysis: (i) in vivo selection, using genetic
complementation of the auxotrophic Escherichia coli
strain KY895 (15) or (ii) in vivo screening on replica
plates, testing for cytotoxicity of NAs (9). The auxo-
trophic selection evaluates library members for thymidine
kinase activity, resulting in a bias toward enzymes with, at
best, a broader substrate speciﬁcity and selecting against
truly orthogonal NA kinases. Replica plating, while
directly assessing for NA activation, is very laborious
and ultimately depends on the cytotoxicity of the phos-
phorylated NA to the host, a criterion that in our tests
in E. coli could not be extended beyond 30-azido-30-
deoxythymidine (AZT). In light of these biases and
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that the limited success in identifying active, orthogonal
NA kinases can largely be attributed to the inadequate
selection or screening techniques.
Inspired by the enzyme library screening methods
for novel proteases and glycosyltransferases based on
ﬂuorescent substrates (16,17), we envisioned a similar
strategy for identifying enzymes that can eﬀectively
phosphorylate NAs. Conceptionally, our idea is based
on two observations: (i) nucleosides and NAs can be eﬃ-
ciently transported across the cell membrane while their
corresponding monophosphates, the product of the
kinase-catalyzed phosphoryl transfer, are trapped inside
the host cytoplasm and (ii) ﬂuorescent nucleoside analogs
(fNAs) with an excitation maxima of >300nm, which
reduces signal interference due to cellular autoﬂuores-
cence, can serve as substrates for dNKs. While the nucleo-
bases of natural nucleosides do possess intrinsic
ﬂuorescence properties under physiological conditions,
direct measurements are impractical due to the com-
pounds’ low quantum yields and overlapping absorption
maxima with aromatic amino acids in proteins and small-
molecule metabolites such as ATP and NADH.
Fortunately, relatively small synthetic modiﬁcations of a
nucleoside’s pyrimidine or purine moiety can red-shift its
absorption spectrum and increase the quantum yield,
enabling detection of these fNAs with high sensitivity in
complex mixtures such as the cytoplasm. As summarized
in Figure 1, a number of ﬂuorescent 20-deoxyribonucleo-
sides, used in DNA structure studies, have been reported
including the etheno-derivative of adenine (8) (18–20), as
well as furano (6) and pyrrolo-pyrimidines (7) and pterines
(9,10) (21–23). We predict that the combination of these
modiﬁed nucleobases with sugar derivatives (11–16),
found in NA prodrugs, generates suitable substrates
for dNK library screening. As outlined in Figure 2,
when bacteria that express individual dNK library mem-
bers are incubated with a fNA, broad-speciﬁcity nucleo-
side transporters facilitate the eﬃcient translocation of the
ﬂuorophor across the membrane (24,25). Production of
fNA-monophosphate in the presence of a functional
fNA kinase will result in accumulation of the ﬂuorophor
in the cytoplasm as its negative charge prevents cellular
export. Fluorescence-activated cell sorting (FACS) can
subsequently be employed to identify and isolate hosts
with the highest ﬂuorescence intensity (17,26).
We herein report the design and validation of
this FACS-based NA kinase screening method, followed
by its application for identifying an orthogonal
30-deoxythymidine (ddT, 1111) kinase from directed
evolution libraries of Drosophila melanogaster 20-
deoxynucleoside kinase (DmdNK). We selected ddT for
these proof-of-principle experiments as it represents a
good example of an NA prodrug whose biological func-
tion is compromised due to lack of phosphorylation. As a
member of the ﬁrst generation of NAs tested for antiviral
therapy, its chemically synthesized triphosphate proved an
eﬀective inhibitor of cellular and viral DNA polymerases
in vitro (27,28). Nevertheless, cell culture experiments
could not reproduce the high level of antiviral activity,
an observation that was largely attributed to ineﬃcient
activation by cellular kinases in vivo (28,29).
As a starting point for enzyme evolution, we chose
DmdNK, a member of the type-I dNK subfamily that
includes the 20-deoxycytidine kinase, 20-deoxyguanosine
kinase and thymidine kinase 2 from human, as well as
Figure 1. Overview of modular nucleoside design. In many nucleoside analogs, a natural pyrimidine (1,2) or purine (3,4) moiety is docked to a sugar
analog (11–16) instead of the native 20-deoxyribosyl portion (5). For the creation of ﬂuorescent NAs, an extension of the heterocycles, as exempliﬁed
in furano and pyrrolo-pyrimidines (6,7), as well as etheno-adenine (8) and pterines (9,10), red-shifts the excitation/emission spectrum of the
nucleobase and increases the quantum yield. When coupled to sugar analogs (11–16), these ﬂuorescent versions of the NA become useful molecular
probes for studying their cellular uptake and metabolism (25).
Nucleic Acids Research, 2009,Vol.37, No. 13 4473several dNKs from insects (30,31). Type-1 dNKs share
a common fold but vary widely in their substrate speciﬁ-
cities and overall catalytic eﬃciencies. DmdNK distin-
guishes itself by showing some of the highest activity
among type-1 dNKs for the four natural 20-deoxyribonu-
cleosides, as well as several NAs (31,32).
MATERIALS AND METHODS
Synthesis of fddT
The ﬂuorescent ddT was prepared in six steps. The details
of the experimental procedures and characterization of the
intermediates are described in the Supplementary Data.
Directed evolution library construction
Random mutagenesis libraries of wild-type DmdNK were
created with the GeneMorph II kit (Stratagene, La Jolla,
CA, USA), using an average mutation frequency of two to
four nucleotide changes per gene (as determined by DNA
sequencing). DNA shuﬄing libraries were prepared by fol-
lowing the nucleotide exchange and excision technology
(NExT) protocol with 33% UTP incorporation (33).
DNA fragments from the mutagenesis libraries and paren-
tal DmdNK were mixed at a 20:1 ratio for reassembly.
Re-engineering of library members for function studies
via site-directed mutagenesis was performed by overlap
extension PCR, following standard protocols (34). Final
PCR products were cloned into pBAD-HisA (Invitrogen,
Carlsbad, CA, USA) via NcoI and HindIII restriction
sites and electroporated into E. coli TOP10 [F-mcrA
D(mrr-hsdRMS-mcrBC) F80lacZDM15 DlacX74 recA1
araD139 D(ara-leu)7697 galU galK rpsL (Str
R) endA1
nupG] (Invitrogen, Carlsbad, CA, USA).
Library screening by fluorescence-activated cell sorting
Library screening was performed by inoculating 2ml LB
media supplemented with ampicillin (50mg/ml) at 378C
until the OD (600nm) reached  0.5. The protein expres-
sion was induced with arabinose (0.2%) and incubation
was continued for 4h. The cell culture was mixed with
5–80mM fNA. For competition experiments, the sample
was complemented with an additional 50–800mM thymi-
dine. After incubation at 378C for 30–120min, cells were
centrifuged and the pellet was washed three times with the
PBS buﬀer (pH 7.4) before being resuspended in the PBS
buﬀer to  1 10
8cells/ml. Cell sorting was performed on
a FACSVantage ﬂow cytometer (Becton Dickinson,
Franklin Lakes, NJ, USA). The event detection was
set to forward and side scattering. Sorting was performed
at <2000 events/s with excitation by a UV laser
(351–364nm) and emission detection through a band
pass ﬁlter (424 20nm). Cells were collected in
Eppendorf tubes, plated on LB-agar plates and harvested
for the DNA sequence analysis and subsequent rounds of
directed evolution.
Kinetic analysis
Selected candidates were subcloned into pMAL-C2x
(New England Biolabs, Beverly, MA, USA) for protein
overexpression and puriﬁcation by amylose aﬃnity chro-
matography according to the manufacturer’s protocol.
The isolated proteins were >95% pure as determined by
SDS–PAGE. Spectrophotometric coupled-enzyme assays
to measure substrate phosphorylation were performed at
378C as described previously (34). The substrate concen-
tration varied from 1mM to 7mM. All experiments were
performed in triplicates and data were ﬁt to the Michaelis–
Menten equation using Origin7 software (OriginLab,
Northhampton, MA, USA).
RESULTS
Fluorescent substrates
While the ﬂuorescent analog of thymidine (fT, 516)i s
commercially available, a synthetic route for ﬂuorescent
ddT (fddT, 6111) was established. Starting with uridine,
we used a three-step synthesis to eliminate the 20 and 30-
hydroxyl groups in the ribose moiety, followed by the
assembly of the furano-pyrimidine portion via palla-
dium-catalyzed cross-coupling chemistry (Figure S1 and
Supplementary Methods). Consistent with the literature,
the excitation and emission wavelengths for both ﬂuores-
cent nucleosides have red-shifted to 331nm and 413nm,
respectively. Separately, we evaluated the impact of the
larger size of the furano pyrimidine moiety, as well as
changes in the protonation of the pyrimidine ring, on
the kinetics of DmdNK (Table 1). In comparison to T
and ddT, the enzyme’s catalytic eﬃciency with the corre-
sponding ﬂuorescent substrates is reduced by a moderate
3-fold. Based on the steady-state kinetics, the decline in
performance is largely attributed to lower turnover rates.
FACS-based screening
Implementing the proposed kinase screen by cellular
entrapment of ﬂuorescent NAs is critically dependent on
three aspects regarding the host organism. Firstly, the host
must be able to eﬃciently take up ﬂuorescent and non-
ﬂuorescent substrates. Secondly, it should be devoid of
endogenous kinases with activity for the ﬂuorescent
nucleosides to improve the signal-to-noise ratio and
avoid false positives. Finally, the host must facilitate the
expression of functional 20-deoxynucleoside kinases.
Escherichia coli is a host organism that meets all three
criteria. The bacterium possesses broad-speciﬁcity nucleo-
side transporters that facilitate eﬃcient transmembrane
Table 1. Comparison of normal and ﬂuorescent substrate phosphory-
lation by 20-deoxynucleoside kinase
Substrate Kcat (s
 1) KM (mM) Kcat/KM (10
3 s
 1M
 1)
T 12.9 0.9 2.7 0.5 4813
fT 5.6 0.3 3.4 0.7 1647
ddT 0.53 0.03 115 22 4.6
fddT 0.18 0.01 139 24 1.3
Kinetic parameters of 20-deoxyribonucleoside kinase from D. melano-
gaster for thymidine (T) and 30-deoxythymidine (ddT), as well as their
corresponding ﬂuorescent analogs, fT and fddT.
4474 Nucleic Acids Research, 2009, Vol. 37,No. 13equilibration of regular NAs and their ﬂuorescent coun-
terparts including furano-pyrimidine derivatives (24).
Furthermore, no interference of host enzymes with the
fddT was detected. Although E. coli carries an endogenous
thymidine kinase, the enzyme belongs to a separate sub-
family [type-II (35,36)] with very strict substrate speciﬁcity
and no detectable in vitro activity for the ﬂuorescent T or
ddT analogs (data not shown). These ﬁndings were con-
ﬁrmed by in vivo validation experiments described below
that did not observe intracellular accumulation of ﬂuores-
cent nucleosides in the absence of an exogenous kinase.
Finally, E. coli is a well-established host organism for the
overexpression of numerous exogenous kinases including
DmdNK and human 20-deoxycytidine kinase (dCK)
(34,37). These two enzymes were used in our validation
experiments with fT; DmdNK is the positive control as
it possesses high thymidine kinase activity and dCK is
the negative control with no detectable activity for
thymidine.
The validation of our fNA screen also included the
evaluation of multiple expression vectors with various
promoters to identify suitable conditions for tunable and
homogeneous kinase production. Initial experiments were
performed with DmdNK under control of lac and T7 pro-
moters (Figure S2). Following induction of the protein
expression, bacterial cultures were incubated with fT and
analyzed by ﬂow cytometry. The latter data indicate
highly variable protein expression levels in individual
cells in the bacterial population. In contrast, uniformly
high kinase expression was observed in the same experi-
ments, using E. coli TOP10 in combination with DNA
vectors carrying the tightly regulated arabinose PBAD pro-
moter (38). Consequently, all experiments for validation
of our screening method and for analysis of the directed
evolution libraries were performed in this expression
system.
A typical ﬂow cytometry histogram for the host carry-
ing either dCK or DmdNK is shown in Figure 2. Under
identical assay conditions, the presence of an exogenous
dNK with thymidine kinase activity results in a 20- to
30-fold increase in cellular ﬂuorescence upon incubation
with fT. More importantly, the signal diﬀerence is suﬃ-
cient to allow for  1000-fold enrichment of E. coli cells
carrying a kinase with the desired substrate speciﬁcity
through cell sorting in the ﬂow cytometer. The enrichment
factor was calculated based on results from sorting experi-
ments with deﬁned mixtures of DmdNK and dCK
(Figure S3). Separately, we veriﬁed the absence of cyto-
toxic eﬀects of the fNAs. The viability of bacteria expres-
sing DmdNK in the presence of up to 200mM of the
ﬂuorescent analog was unaﬀected (data not shown).
Directed evolution
Next, our FACS-based screening technique was applied
toward the laboratory evolution of an orthogonal ddT
kinase, starting with the fruitﬂy enzyme DmdNK.
Following three rounds of random mutagenesis and one
round of DNA shuﬄing, libraries were screened for
kinases with increased activity for fddT. Evaluating
between 300000 and 500000 cells per round of FACS,
the sorting gate was set to collect the top 0.5% of highly
ﬂuorescent cells. The selection pressure for NA activity
was gradually raised over subsequent rounds of screening.
To favor kinases that tightly bind fddT, its concentration
was lowered from initially 80mMt o5 mM in the ﬁnal
round. Furthermore, the exposure time of cells to
new round /
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Figure 2. Schematic overview of the kinase library screening assay with ﬂuorescent NAs. Upon incubation of bacteria with the target fNA, cells that
carry a functional kinase variant for the speciﬁc substrate will accumulate the fNA monophosphate. Hosts cells with the highest ﬂuorescence intensity
can be identiﬁed and isolated by ﬂuorescence-activated cell sorting (FACS) for subsequent characterization of the library member or, if desirable,
another round of directed evolution. For concept validation, E. coli TOP10 expressing exogenous DmdNK with thymidine kinase activity (+kinase)
was compared to host expressing thymidine kinase-deﬁcient human dCK ( kinase). The histogram shows the 20- to 30-fold increase in cellular
ﬂuorescence upon incubation with fT in the presence of the exogenous thymidine kinase activity.
Nucleic Acids Research, 2009,Vol.37, No. 13 4475ﬂuorescent substrate was shortened from 120 to 30min to
favor enzymes with higher fNA turnover. Finally, the
addition of up to 800mM thymidine to compete with
fNA binding gave preference to library members with
reduced aﬃnity for the native substrates.
After the ﬁnal round of directed evolution, 13 selected
candidates were characterized by DNA sequencing.
The analysis indicated that the genes carry four to eight
expressed mutations (Figure S4). Besides several one-time
substitutions, eight positions (T85M, S123L, A147V,
E172V, Y179F, H193Y, Q198H and S224C) were found
in two or more sequences. Among these variants, the
substitutions in positions 147, 198 and 224 were consid-
ered neutral, involving conservative changes in regions
distant to the active site, and were therefore excluded
from further analysis. A preliminary screening of the
remaining enzymes for substrate speciﬁcity quickly identi-
ﬁed the three variants with a mutation in position E172 as
the most promising candidates. Variant R4.V1 (round 4;
variant 1) carries a total of eight amino acid substitutions
(T85M, S123L, A147V, E172V, D189E, H193Y, N210D,
S223G), R4.V3 contains four changes (T85M, E172V,
Y179F and H193Y) and R4.V9 has six mutations
(T85M, S123L, N130D, E172V, H193Y and L203I). The
three variants were overexpressed and puriﬁed to homo-
geneity for subsequent kinetic characterization.
Kinetic analysis
For the overexpression of the selected kinases, library
members were fused to maltose-binding protein (MBP)
as a puriﬁcation tag that has the additional beneﬁt of
increasing enzyme stability. We established in separate
experiments that the N-terminal MBP does not have a
signiﬁcant eﬀect on the kinetic properties of the wild-
type enzymes (data not shown). Following puriﬁcation,
we measured the steady-state kinetics of R4.V1, R4.V3
and R4.V9 to evaluate their catalytic performance with
the four natural 20-deoxynucleosides, as well as the two
NAs ddT and fddT (Table 2). All three candidates showed
a similar overall shift in the catalytic performance. For T
and dC, the kcat/KM values declined by three to four
orders of magnitude. The weaker performance resulted
from a drop in catalytic activities and higher Michaelis–
Menten constants. In the case of dA and dG, the catalytic
eﬃciency dropped by two to three orders of magnitude,
largely due to declines in turnover. In contrast, the cata-
lytic performance of the three variants with ddT and fddT
remained unchanged relative to DmdNK (<2-fold).
While the kinetic parameters for ddT stayed the same,
the KM values for fddT dropped 5- to 10-fold but were
accompanied by a decline in activity of similar magnitude,
leaving the speciﬁcity constant unchanged.
Among the three kinase variants, R4.V3 showed
the most favorable change in performance. The substrate
speciﬁcity of R4.V3, deﬁned by [kcat/KM(NA)]/[kcat/
KM(T)], indicates a 20- and 30-fold preference for ddT
and fddT over T. These results suggest a change in sub-
strate speciﬁcity by over four orders of magnitude, eﬀec-
tively reversing the enzyme’s substrate preference
compared to DmdNK whose kinetic data show a 1000- to
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4476 Nucleic Acids Research, 2009, Vol. 37,No. 133700-fold greater performance for T over fddT and ddT,
respectively. Intrigued by the observation that the fewest
number of mutations cause the most signiﬁcant changes
in function, we further investigated the individual contri-
butions of the four mutations in R4.V3 by reverse
engineering.
Reverse engineering
The role of the four mutations in R4.V3 (Figure 3) was
evaluated by reversing individual amino acid substitu-
tions, followed by overexpression, puriﬁcation and kinetic
characterization of the new variant (Table 3). The most
dramatic change was observed in R4.V3-[172]. Replacing
V172 with the original glutamate raises the level of activity
for the native substrates by two to three orders of magni-
tude. R4.V3-[172] shows parent-like turnover numbers but
2- to 16-fold higher KM values compared to DmdNK,
compromising its wild-type-like overall performance.
The F179Y substitution in R4.V3-[179] also contributes
toward the recovery of the wild-type activity, yielding a
10-fold higher catalytic eﬃciency than R.V3 for the native
substrates as a result of improvements in kcat and KM
values. Together, the two mutations are responsible for
R4.V3 discriminating against natural substrates, yet not
even one of the two substitutions seems to have a major
eﬀect on the kinetic parameters for ddT (<2-fold).
E172V
Y179F
H193Y
T85M
T
O
P
-
V
I
E
W
S
I
D
E
-
V
I
E
W
E172
Y179
3.2 Å
4.2 Å
2.9 Å
T85 V84
M88
Q81
C A
B D
Figure 3. Structure model of R4.V3. The locations of the four mutations are highlighted in DmdNK with thymidine, bound in the phosphoryl
acceptor-binding site (PDB access no.: 1OT3 (40)). The top (A) and side view (B)o fDmdNK show the close proximity of E172V (light blue) and
Y179F (dark blue) to the substrate while H193Y (orange) and T85M (red) are located in more distant locations to the active site. (C) The close-up
view of the active site shows the direct hydrogen-bonding interactions of E172 with the 30-OH group of the substrate’s ribose moiety. The OH group
of Y179 contacts the same position on the substrate via bridging water. (D) The modeled overlay of thymidine (gray) and fT (green) in the active site
of DmdNK indicates a potential steric clash of the ﬂuorescent substrate’s furano moiety with V84 and M88. The T85M mutation is believed to cause
a slight conformational shift of the helical region, creating a more favorable binding pocket for substrates with modiﬁcations in the C4/C5 position
of the nucleobase. Figures were created with PyMOL software (DeLano Sci., Palo Alto, CA).
Nucleic Acids Research, 2009,Vol.37, No. 13 4477As for the two mutations distant to the active site, swap-
ping Y193 back to the original histidine in R4.V3-[193]
leads to only minor changes in the kinetic performance,
indicating that the mutation is not relevant for the
observed changes in substrate speciﬁcity. In contrast,
the reversion of T85M shows an unexpected eﬀect on
the enzyme’s substrate speciﬁcity. While leaving the
catalytic eﬃciency for 20-deoxycytidine and the purine
substrates unaﬀected, R4.V3-[85] exhibits 10- and
14-fold higher kcat/KM values for ddT and T, respectively.
For both substrates, the improvements result from
approximately 3-fold higher turnover numbers and
3-fold lower apparent binding constants, raising questions
about the selection for T85M during the directed evolu-
tion experiments. An indicator for the functional role
of position 85 is provided by the change in the kinetic
properties of R4.V3-[85] for fddT. The enzyme’s 8-fold
rise in KM(fddT) compared to R4.V3, which translates
into a 5-fold lower catalytic eﬃciency, hints that the
substitution is involved in remodeling the substrate
nucleobase binding pocket.
DISCUSSION
Deoxynucleoside kinases are important targets for protein
engineering, due to their role in NA prodrug activation
and potential application in suicide gene therapy. Ideally,
an engineered kinase should exhibit high activity for the
NA while eﬀectively discriminating against phosphoryla-
tion of native substrates to avoid unbalancing the cellular
dNTP pool (39). In the absence of known native kinases
for NAs, the tailoring of enzymes by various directed evo-
lution strategies have been attempted, yet has had limited
success due to a lack of selection or screening methods
to directly identify library members with the desired
NA activity (9–14). Here, we have established a novel
screening method, using ﬂuorescent analogs of natural
20-deoxynucleosides and NAs in combination with
FACS, to identify and isolate enzymes with enhanced spe-
ciﬁcity and activity for these substrates.
For the proof of principle, we used fddT as the target
substrate to search for an orthogonal ddT kinase. After
four rounds of directed evolution, kinetic analysis of
selected candidates revealed a dramatic shift from the
parental enzyme’s preference for the 20-deoxyribosyl
moiety to the 20,30-dideoxyribose derivative. Our most suc-
cessful variant R4.V3 shows a change in substrate speciﬁ-
city by more than four orders of magnitude, now favoring
ddT over dC and T by an 8- and 30-fold higher catalytic
eﬃciency, respectively. As such, our screening protocol
has been eﬀective in identifying ‘loss-of-function’ variants
that gain NA speciﬁcity by suppressing eﬃcient phosphor-
ylation of natural 20-deoxynucleosides. Nevertheless,
a desired simultaneous ‘gain-in-function’ for fddT (and
ddT) was not observed in R4.V3. While the 10-fold
increase in kcat/KM for ddT in R4.V3-[T85] indicates
the possibility for improvement, we hypothesize that
more substantial increases in activity for NAs with a
20,30-dideoxyribose moiety might be diﬃcult to achieve
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4478 Nucleic Acids Research, 2009, Vol. 37,No. 13due to the sugar’s deﬁciency in functional groups that
compromises productive substrate binding.
Nevertheless, our evolved ddT kinase performs
very favorably under physiological conditions. Despite
the largely unchanged kinetic parameters of R4.V3 for
ddT and fddT in vitro, the true functional beneﬁt of
R4.V3 in regard to selective ddT phosphorylation is
apparent under competitive substrate conditions in vivo
(Figure 4). The incubation of bacteria, expressing either
R4.V3 or DmdNK, with the same fddT/T substrate mix-
ture shows substantially higher cellular ﬂuorescence in the
hosts carrying the engineered kinase (Figure 4B). Rather
than selecting a candidate with a greatly enhanced cataly-
tic activity for fddT, the ability of R4.V3 to eliminate the
competition of natural 20-deoxynucleosides for occupancy
of the active site seems an equally successful strategy for
increasing NA phosphorylation in vivo. As the intracellu-
lar concentration of natural deoxynucleosides normally
does not exceed 10mM (39), the KM values of R4.V3
above 90mM for the native substrates should largely elim-
inate competition for the active site.
We next evaluated the contributions of the four muta-
tions in R4.V3 toward the observed functional changes by
reverse engineering. The substitutions in positions 172 and
179 show the most dramatic impact on substrate speciﬁ-
city and are likely a direct consequence of the ribose
modiﬁcations in fddT (Figure 3C). In DmdNK, the two
residues are part of the active site and, according to the
crystal structure, form hydrogen-bonding interactions
directly (E172) or via a water molecule (Y179) to the
30-hydroxyl group of the phosphoryl acceptor (40).
Mutations in these two otherwise highly conserved posi-
tions have not previously been observed in engineered
kinases, a fact that we attribute to biases resulting from
the library analysis for thymidine kinase activity in the
E. coli auxotroph KY895. The two active site mutations
E172V and Y179F not only eliminate the favorable hydro-
gen-bonding interactions but also actively discriminate
against the native substrates by optimizing the binding
pocket for the more hydrophobic 20,30-dideoxyribose
moiety of ddT. Consistent with this interpretation, our
kinetic data suggest that simultaneous reversion of these
two mutations restores the catalytic activity for the native
substrates to wild-type levels (Table 3).
In contrast, the changes in residues 85 and 193 are not
obvious as the two positions lack proximity to the sub-
strate. While our study conﬁrms the mutation in position
193 as neutral, the reversion of T85M in R4.V3-[85] results
in a 10-fold improvement in the catalytic performance for
ddT and T while diminishing kcat/KM for fddT by raising
KM by a similar magnitude. Based on the observation that
the eﬀect is thymine speciﬁc, we argue that T85M is a
response to substitutions in C-4/5 of the nucleobase
of fddT. The introduction of the furano moiety in
our fNAs adds an extended, sterically rigid substituent
at C-4/5 of the pyrimidine. This extra bulk leads to unfa-
vorable interactions and potential steric clashes with side
chains of V84 and M88 in the active site binding pocket,
an eﬀect that the enzyme could compensate for by mutat-
ing the neighboring T85 (Figure 3D). As the side chain of
T85 points away from the active site, packing tightly
against a neighboring helix in the protein structure, we
speculate that the mutation at position 85 results in
a slight repositioning of the helix that carries residues
84–88, thereby enlarging the binding pocket and
allowing for more favorable binding interactions of the
A
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Figure 4. In vivo competition experiments in E. coli, studying the cellular accumulation of ﬂuorescent ddT in the presence of increasing amounts of
thymidine (1–100-fold molar excess of thymidine). (A) Bacteria expressing members of the fourth-round kinase library (black line) consistently
outperform cells expressing DmdNK (gray line). At 80mM fddT + 80mM thymidine (1:1), the library shows approximately 10-fold higher ﬂuores-
cence intensity over the wild-type enzyme. Although the favorable ratio decreases with increasing thymidine concentration, a direct consequence of
the two substrates’ competition for the active site, the evolved kinases slightly surpass DmdNK even at 8mM thymidine (100:1). (B) Cellular
accumulation of fddT (10mM) in bacteria expressing R4.V3 (black) or DmdNK (gray) in the presence of a 10-fold molar excess of thymidine
(100mM). The 5-fold higher ﬂuorescence intensity for R4.V3 conﬁrms kinetic data of improved substrate speciﬁcity for the evolved kinase and
demonstrates its relevance to performance in the complex cellular environment.
Nucleic Acids Research, 2009,Vol.37, No. 13 4479furano–pyrimidine moiety. Mutations in position 85 have
previously been observed in the engineering of DmdNK
and were rationalized by the residue’s importance in deﬁn-
ing the topology of the phosphoryl acceptor-binding site
(11). While eﬀorts to further investigate this hypothesis are
in progress, the results from our reverse engineering indi-
cate that the eﬀect of T85M is strictly additive, enabling us
to generate an improved kinase for the non-ﬂuorescent
ddT by simply reversing this mutation. Furthermore, the
kinetic data for R4.V3-[85] show that the two active site
mutations in positions 172 and 179 are not neutral in
regard to ddT phosphorylation but are responsible for a
6-fold increase in the catalytic eﬃciency over the parental
DmdNK.
The comparison of our engineered kinases with variants
from previous directed evolution experiments further
emphasizes the beneﬁts of direct screening for NA activa-
tion. The best variants of HSV–thymidine kinase (9,13)
and DmdNK (11,12,41) typically show <2-fold gains in
kcat/KM for the NA. Furthermore, mutants selected by
genetic complementation or cytotoxicity screening retain
high activity for the native substrate. The most selective
mutants of HSV–thymidine kinase show a preference for
NA over thymidine (kcat/KM(NA) or kcat/KM(thymidine))
of 0.63 for AZT (9) and 0.17 for ganciclovir (13). For
DmdNK, the highest NA preference reported for AZT is
0.14 (11) while ddC reaches 0.39 (41). In contrast, the NA
preference of R4.V3[T85] for ddT is 20. The ability of
an evolved NA kinase to discriminate against native
20-deoxynucleosides is advantageous as it improves its per-
formance in vivo by reducing competition for substrate
binding to the enzyme active site. As shown in Figure 4,
a series of ﬂow cytometry experiments demonstrates the
preferred phosphorylation of fddT by R4.V3, even in the
presence of up to 100-fold molar excess of the competing
native thymidine. In addition, the elevated speciﬁcity also
reduces the risk of potential side eﬀects due to ﬂuctuations
in the cellular dNTP concentration. Although the long-
term eﬀects of auxiliary dNKs on a host organism were
not addressed in our study, preventing the unregulated
phosphorylation of natural 20-deoxynucleosides should
minimize their potential to interfere with other metabolic
processes and DNA replication ﬁdelity.
Finally, we anticipate directed evolution of kinases in
combination with fNA screening to be a general strategy
for identifying orthogonal NA kinases. Similar to the syn-
thesis of fddT, other sugar moieties (for example 12–16)
can be combined with one of the ﬂuorescent nucleobases
(6–10), giving access to a large number of potential sub-
strates for FACS-based screening of kinase libraries.
Similarly, the screening protocol can be adapted to other
members of the type-1 dNK family. Human dNKs are of
particular interest for creating orthogonal NA kinases as
they reduce the risk of undesirable immunogenic response
in clinical applications. Separately, the screening of kinase
libraries with ﬂuorescent substrates could be adapted to
the eukaryotic expression system such as Saccharomyces
cerevisiae or mammalian cell lines. Both are well suited for
FACS and could further optimize the search process for
novel NA kinases. Such novel kinases could not only
improve the potency of existing prodrugs but also oﬀer
a second chance for NAs that failed in previous clinical
studies due to a lack of phosphorylation by endogenous
dNKs. As such, the development of kinases tailored to a
NA of choice sets the stage for clinical studies testing the
co-administration of enzyme plus small-molecule prodrug
and potentially introduces a large number of new antiviral
and cancer prodrugs.
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